Stockreport
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a moderated panel discussion at the BMO 2026 Metabolic Health Summit, to be held in New York, NY, on Tuesday, March 24, 2026. Corbus is advancing CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. CRB-913 demonstrated potent, rapid weight loss and favorable GI tolerability in a 14-day Phase 1a SAD/MAD study, suggesting this drug could provide a novel long-term weight management solution for people struggling with chronic obesity. Corbus expects to complete an ongoing Phase 1b dose-ranging 12-week study (n=240) in summer 2026. BMO 2026 Metabolic Health SummitEmerging Companies Panel: What's Next in the Treatment of Metabolic DiseaseDate: March 24,
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CRBP | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CRBP alerts
CRBP alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
NEWS
NEWS
- How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% [Yahoo! Finance][Yahoo! Finance]
- Corbus Pharmaceuticals (CRBP) had its price target raised by Oppenheimer Holdings, Inc. from $53.00 to $57.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance][Yahoo! Finance]
- Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update[GlobeNewswire]
- Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead [Yahoo! Finance][Yahoo! Finance]
- More
CRBP
SEC Filings
SEC Filings
- 3/11/26 - Form S-3
- 3/9/26 - Form 10-K
- 3/9/26 - Form 8-K
- CRBP's page on the SEC website
- More